Jul 20, 2017
Julie is an executive
pharmaceutical leader with over 20 years of experience across all
phases of development both on the commercial and research sides of
the organization. She leverages her Masters in Business
Administration and Doctorate of Pharmacy to develop and deliver
strategic patient-centric value propositions to optimize patient
access and improve outcomes in patients with difficult to treat
diseases leading to longer, healthier, and more productive lives.
Her years of experience in global and US payer markets provides
Julie with intimate knowledge of the current and evolving payer and
market access landscape in the US and around the globe. She has led
the development and execution of several outcomes-based contracts
with 3 of the largest national payer organizations in the US.
Dr. Locklear is well published, having authored >30 publications in peer-reviewed journals and >60 peer-reviewed abstracts presented as posters at major scientific congresses.
00:00 Innovation in Pharma.
04:00 “Improving patient outcomes is the goal.”
04:50 The key elements to a Value-Based contract.
05:15 “The Payer is going to need to be able to collect data.”
06:00 Look at available literature.
07:30 “Success really just means ability and feasibility.”
09:10 Review the efficacy and effectiveness of a drug.
10:00 Advice for barriers Julie has encountered.
13:00 Looking at adherence over time before looking at the actual outcome.
17:45 Patient Outcomes that matter.
18:50 The accelerating pace of Value-Based agreements.
20:30 “The right drug for the right patient at the right time.”
24:45 “The number is much larger than what you’re seeing in the public domain.”
25:00 Two examples of these Value-Based contracts.
28:00 How Action Plans change for different Payers and Stakeholders.